Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Corixa Corp.

Division of GlaxoSmithKline PLC

Latest From Corixa Corp.

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth

Hopes For Glaxo’s MAGE-A3 Vaccine Grow Dim As Trial Misses Endpoint

Glaxo’s vaccine fails co-primary endpoint in Phase III DERMA study of melanoma – trial is allowed to continue but hopes for success are not high. Top-line release raises specter that drug could become yet another failed cancer vaccine.

Clinical Trials Research and Development Strategies

Flu Speed Ahead in Vaccines Market

Large investments by GlaxoSmithKline and Novartis in the US flu vaccine business highlight a rush back into the business. Government subsidies, technical assistance and market creation are making the flu vaccine field an attractive section of the pharma field again. It has been generally viewed for decades as a risky, difficult buisness with very little growth potential. Now the tables have turned.
Business Strategies Regulation

Vaccines Enter the New Age of Adjuvants

The US vaccine industry is a year away from a wave of new, more effective and longer-lasting adjuvant-enhanced products. The technology promises added protection to patients-and extra proprietary rights to product marketers.
BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Steven Gillis, PhD, Chmn. & CEO
    Michelle Burris, SVP, CFO
    Steve Reed, PhD, EVP, CSO
    Chris E Rivera, VP, Sales
  • Contact Info
  • Corixa Corp.
    Phone: (206) 754-5711
    1124 Columbia St.
    Ste. 200
    Seattle, WA 98104